Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells

Cholangiocarcinoma (CCA) is a lethal cancer with rapid progression and poor survival. Novel and more effective therapies than those currently available are, therefore, urgently needed. Our research group previously reported the combination of gemcitabine and cytotoxic T lymphocytes to be more effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Wathikthinnakon, Methi, Luangwattananun, Piriya, Sawasdee, Nunghathai, Chiawpanit, Chutipa, Lee, Vannajan Sanghiran, Nimmanpipug, Piyarat, Tragoolpua, Yingmanee, Rotarayanont, Siriphorn, Sangsuwannukul, Thanich, Phanthaphol, Nattaporn, Wutti-in, Yupanun, Somboonpatarakun, Chalermchai, Chieochansin, Thaweesak, Junking, Mutita, Sujjitjoon, Jatuporn, Yenchitsomanus, Pa-thai, Panya, Aussara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007942/
https://www.ncbi.nlm.nih.gov/pubmed/35418130
http://dx.doi.org/10.1038/s41598-022-09964-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007942/
https://www.ncbi.nlm.nih.gov/pubmed/35418130
http://dx.doi.org/10.1038/s41598-022-09964-6

Ejemplares similares